• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ME Guowen,LIU Shichang,WANG Hailiang,JIANG Wenyan,WANG Xuejian.Research Status of New lipid-lowering Drugs PCSK9 Inhibitors in Arteriosclerosis Cardiovascular Disease[J].Journal Of Pharmaceutical Research,2024,43(5):487-494[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2913times   Download 2795次 QR Code for this article
Scan with your phone!
新型降脂药物PCSK9抑制剂在动脉粥样硬化心血管疾病的研究现状
马国文1,2,刘世昌3,王海亮2,姜文妍1,王学健1
Font:Larger+|Default|Smaller-
(1.山东第二医科大学药学院,山东 潍坊 261053;2.潍坊市人民医院,山东 潍坊 261041;3.潍坊市精神卫生中心,山东 潍坊 261072)
摘要:
动脉粥样硬化是许多心血管疾病的早期病理改变,脂质代谢紊乱是动脉粥样硬化性心血管疾病(ASCVD)最重要的危险因素之一。前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型 (PCSK9) 是血脂调节的关键因子,可以通过与低密度脂蛋白受体(LDLR)结合,降解LDLR从而阻止低密度脂蛋白的清除,导致低密度脂蛋白胆固醇(LDL-C)水平升高,增加心血管疾病的风险。PCSK9也参与炎症细胞因子的生成、内皮功能障碍和动脉粥样硬化斑块的形成。多项研究显示,PCSK9是治疗ASCVD的一个有希望的新靶点。PCSK9抑制剂是目前治疗高胆固醇血症的新型药物。本文就PCSK9抑制剂在动脉粥样硬化中的作用及药物研究进展做一综述,为临床用药提供参考。
关键词:  前蛋白转化酶枯草杆菌蛋白酶/kexin9型抑制剂  动脉粥样硬化  人前蛋白转化酶枯草溶菌素9  动脉粥样硬化性心血管疾病  胆固醇  低密度脂蛋白胆固醇
DOI:10.13506/j.cnki.jpr.2024.05.013
基金项目:山东省高等学校科技计划项目(No.J15LM58)
Publication Date:May 25, 2024
Research Status of New lipid-lowering Drugs PCSK9 Inhibitors in Arteriosclerosis Cardiovascular Disease
ME Guowen1,2,LIU Shichang3,WANG Hailiang2,JIANG Wenyan1,WANG Xuejian1
(1.College of Pharmacy, Weifang Medical College, Weifang 261053, China;2.Weifang People’s Hospital, Weifang 261041, China;3.Weifang Mental Health Center, Weifang 261072, China)
Abstract:
Atherosclerosis is an early pathological change of many cardiovascular diseases. Lipid metabolism disorder is one of the most important risk factors of atherosclerotic cardiovascular disease (ASCVD). Proprotein conver-tase subtilisin/kexin type 9 (PCSK9) is a key protein in lipid metabolism. It can bind to low-density lipoprotein receptor (LDLR) and degrade LDLR to prevent the clearance of low-density lipoprotein, resulting in increased Low density lipoprotein cholesterol (LDL-C) levels. Increased risk of cardiovascular disease. PCSK9 is also involved in the production of inflammatory cytokines, endothelial dysfunction and the formation of atherosclerotic plaques. A number of studies have shown that PCSK9 is a promising new target for the treatment of ASCVD.PCSK9 inhibitors are currently a new type of drug for the treatment of hypercholesterolemia. This article reviews the role of PCSK9 inhibitors in atherosclerosis and the research progress of drugs, so as to provide reference for clinical medication.
Key words:  Proprotein convertase 9 inhibitors  Atherosclerosis  Human proprotein convertase subtilisin/kexin type 9 inhibitor  ASCVD  Cholesterol  Low-density lipoprotein cholesterol
Today's Visits:488    Total Visits:2383203
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.